Mumbai based Lupin Limited (Lupin) and Mylan N.V. in the US have announced the launch of Nepexto® , biosimilar etanercept, in the German market.

Nepexto® is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile idiopathic arthritis from the age of 2 years, active and progressive psoriatic arthritis, severe axial spondyloarthritis, moderate to severe plaque psoriasis and chronic severe plaque psoriasis in children and adolescents from the age of 6 years.

Nepexto® is approved for all therapeutic indications of the reference product Enbrel® .

The Tumor Necrosis Factor (TNF) inhibitor etanercept was first approved for the treatment of rheumatoid arthritis in Germany in 2000 and since then has offered an effective treatment option for several chronic inflammatory diseases.

Nepexto® is available as a solution for injection in a pre-filled pen and pre-filled syringe . Data show a high patient acceptance of the easy-to-handle pre-filled pen. Patients favored this latex-free device for selfinjection, which can lead to improvement in compliance.

Nepexto® , with an equivalent efficacy and safety to reference product Enbrel®, is an attractive cost-effective treatment alternative that can contribute to sustainable healthcare and treatment options.

Nepexto is the second immunology product to be introduced into the German market. In addition to Hulio®, an adalimumab biosimilar, Nepexto® expands Mylan’s therapeutic portfolio for the effective treatment of various immune-mediated diseases including rheumatoid arthritis.